Supplementary Online Content

Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM. Understanding flares in patients with generalized pustular psoriasis documented in US electronic health records. *JAMA Dermatol.* Published online August 10, 2022. doi:10.1001/jamadermatol.2022.3142

eTable 1. Lists of Terms and Attributes
eTable 2. List of Medications
eFigure. Sensitivity Analysis of Comparison of Flare Episodes With and Without No Treatment

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable 1. Lists of Terms and Attributes**

| **FLARE**                          | **PUSTULE/LESION**                  | **RASH/ERYTHEMA**                  | **EXAMPLE FLARE ATTRIBUTES*** |
|------------------------------------|-------------------------------------|------------------------------------|-----------------------------|
| FLARE                              | PUSTULE                             | RASH                               | PROGRESSION                 |
| ERUPTION                           | PUSTULAR RASH                       | SKIN RASH                          | PERSISTENT                  |
| FLARING                            | PAPULOPUSTULE LESION                | DRUG RASH                          | RECURRENT                   |
| SKIN ERUPTION                      | SKIN LESION                         | PUSTULAR RASH                      | INCREASE                    |
| DRUG ERUPTION                      | BLISTER                             | PRURITIC RASH                      | MORE                        |
| CUTANEOUS ERUPTION                 | BOIL                                | MACULAR RASH                       | QUITE                       |
| ERUPTION OF THE SKIN               | NODULE                              | ERYTHEMA                           | WORSE                       |
| MACULAR ERUPTION                   |                                     | ERYTHRODERMA                       | DECOMPENSATION              |
| BLISTERING ERUPTION                |                                     | REDNESS                            |                             |
| BLISTER FORMATION                  |                                     | RED SKIN                           |                             |
|                                   |                                     | INFLAMMATION                       |                             |

* All variations of terms were used. For example, ‘worse’ also included worsen, worsens, worsened, and worsening.
**Table 2.** List of Medications

| Drug category         | Name                                                                 |
|-----------------------|----------------------------------------------------------------------|
| ORAL CORTICOSTEROIDS | PREDNISONE, TRIAMCINOLONE, HYDROCORTISONE, DEXAMETHASONE            |
| OTHER ORALS           | CYCLOSPORINE, METHOTREXATE, MYCOPHENOLATE MOFETIL, SULFASALAZINE, TACROLIMUS |
| ORAL RETINOIDS        | ACITRETIN                                                             |
| OTHER TOPICALS        | CALCIPOTRIENE, CALCITRIOL                                            |
| IL INHIBITORS         | ANAKINRA, GEVOKIZUMAB, CANAKINUMAB, SARILUMAB, TOCILIZUMAB, USTEKINUMAB, IXEKIZUMAB, SECUKINUMAB, BRODALUMAB, GUSELKUMAB, TILDRAKIZUMAB, RISANKIZUMAB |
| TNF INHIBITORS        | ADALIMUMAB, CERTOLIZUMAB, ETANERCEPT, GOLUMUMAB, INFliximab          |
| T-CELL INHIBITORS     | ABATACEPT                                                             |
| PDE-4 INHIBITORS      | APREMILAST                                                            |
| JAK INHIBITORS        | TOFACITINIB, BARICTINIB, UPADACITINIB                                 |
| CD-20 ANITIBODY       | RITUXIMAB                                                             |
**eFigure.** Sensitivity Analysis of Comparison of Flare Episodes With and Without No Treatment

Supplemental Figure 1 breaks down Figure 3 showing the treatment before, during, and after flare episodes for two subgroups: episodes that did and did not have treatment initiated during a flare episode.

| Treatment Category | Flare episodes with treatment during episode (N=302) | Flare episodes with no treatment during episode (N=211) |
|--------------------|-----------------------------------------------------|-------------------------------------------------------|
| Topical steroids    | 16%                                                 | 10%                                                  |
| Other topicals      | 2% 7%                                               | 4% 0%                                                 |
| Oral corticosteroids| 7% 9%                                               | 7% 3%                                                 |
| Oral retinoids      | 3% 7%                                               | 3% 2%                                                 |
| Other orals         | 11% 0%                                              | 15% 6%                                                |
| Phototherapy        | 1% 0%                                               | 0% 0%                                                 |
| TNF inhibitors      | 4% 6%                                               | 4% 9%                                                 |
| IL inhibitors       | 4% 2%                                               | 5% 3%                                                 |
| PDE-4 inhibitor     | 1% 3%                                               | 5% 4%                                                 |
| Opioids             | 20% 18%                                             | 22% 16%                                               |

Percent of flare episodes